Core Technology

ENERGI-F702

The World Health Organization (WTO) employs diabetes as the criteria in defining metabolic syndrome, blaming the syndrome on the resistance of insulin, which leads to overweight, high blood glucose, hyperlipemia, and hypertension. Energenesis Biomedical's ENERGI-F702 is proven to be capable of stimulating glucose transporting protein 4 (GLUT4) expression, which facilitates transfer of GLUT4 to cell membrane and thereby increases capability of cells to absorb glucose. Study on second-type diabetic model mice (db/db mice) shows that feeding of F702 to diabetic small mice, in long- or short-term, can increase tolerance for glucose and will not lead to extra weight, unlike Rosiglitazone, a TZD-type hypoglycemics.